NSE: CIPLA | BSE: 500087

Strong Performer, Getting Expensive

Download real time

1564.00 3.00 (0.19%)

2.6M NSE+BSE Volume

NSE 14 Aug, 2025 3:31 PM (IST)

126,332.7

Market Cap

High in industry

0.7

Beta 1Year

Very Low volatility

Cipla Ltd. share price target and research reports

Latest analyst research reports with target prices and PDF download for CIPLA, BSE:500087 Cipla Ltd.

Search Inside the pdf :

Cipla Ltd.

28 Jul 2025

1564.00

0.19%

Result Update:Cipla

Buy: Cipla Ltd.

Axis Direct

We remain positive on the stock with a BUY rating and arrive at a target price of Rs 1,700 per share.

Axis Direct released a Buy report for Cipla Ltd. with a price target of 1700.0 on 28 Jul, 2025.

Cipla Ltd.

27 Jul 2025

1564.00

0.19%

Cipla (CIPLA IN) Q1FY26 Result Update Strong US...

Buy: Cipla Ltd.

Prabhudas Lilladhar

CIPLA's Q1FY26 EBITDA (Rs17.8bn; 25.6% OPM) was 6% ahead of our estimates. Cipla managed to deliver strong margins during the quarter. During the quarter company witnessed price erosion for its generic products which was offset by new launches such as gAbraxane. Mgmt guided strong US revenues of $1bn for FY27 despite gRevlimid erosion. We expect Cipla to maintain its existing US sales run-rate. This will be aided by several high value niche launches in the US like gAbraxane, Nilotininb, gAdvair. Further, Cipla's...

Cipla Ltd. is trading above all available SMAs

Cipla Ltd.

26 Jul 2025

1564.00

0.19%

US business on a strong footing

Buy: Cipla Ltd.

Target

ICICI Securities Limited

Cipla reported an in-line Q1FY26 result led by growth across the US and South Africa. Despite price erosion in gRevlimid, it posted a 156bps YoY (+133bps QoQ) surge in gross margin to 68.8%.

Cipla Ltd. is trading above all available SMAs

Cipla Ltd.

14 May 2025

1564.00

0.19%

Cipla (CIPLA IN) Q4FY25 Result Update In-line EBITDA;...

Buy: Cipla Ltd.

Prabhudas Lilladhar

CIPLA's Q4FY25 EBITDA (Rs15.4bn; 22.8% OPM) was in line with our estimates. While Q4 is seasonally weak quarter; margins at 23% were above our estimate. Despite delay in new launches and supply issues of gLanreotide; Cipla managed to deliver strong profitability/margins in H2FY25. We expect Cipla to maintain its existing US sales run-rate. This will be aided by several high value niche launches in the US like gAbraxane, Nilotininb, gAdvair. Further, Cipla's...

Cipla Ltd. is trading above all available SMAs

Cipla Ltd.

11 Apr 2025

1564.00

0.19%

Cipla (CIPLA IN) Event Update Gets approval for...

Buy: Cipla Ltd.

Prabhudas Lilladhar

Cipla has secured its much awaited USFDA approval of gAbraxane following Change in Estimates | Target | Reco the Goa facility clearance in November 2024, milestone that reinforces our positive stance on the company. Our FY26E and FY27E EPS factors in...

Axis Direct released a Buy report for Cipla Ltd. with a price target of 1700.0 on 28 Jul, 2025.

Cipla Ltd.

29 Jan 2025

1564.00

0.19%

CIPLA LTD.

Buy: Cipla Ltd.

Prabhudas Lilladhar

Axis Direct released a Buy report for Cipla Ltd. with a price target of 1700.0 on 28 Jul, 2025.

Cipla Ltd.

29 Jan 2025

1564.00

0.19%

Result Update:Cipla

Buy: Cipla Ltd.

Axis Direct

We maintain our BUY recommendation with a target price of Rs 1,700/share.

Axis Direct released a Buy report for Cipla Ltd. with a price target of 1700.0 on 28 Jul, 2025.

Cipla Ltd.

28 Jan 2025

1564.00

0.19%

3Q results beat estimates; yet to scale up Lanreotide supply

Neutral: Cipla Ltd.

Recommendation Target

Motilal Oswal

CIPLA delivered better-than-expected 3QFY25 earnings. While revenue was in line, EBITDA/adj. PAT beat our estimates, aided by a better product mix and lower R&D spending.

Axis Direct released a Buy report for Cipla Ltd. with a price target of 1700.0 on 28 Jul, 2025.

Cipla Ltd.

17 Jan 2025

1564.00

0.19%

Empowering health, Enriching Lives

Accumulate: Cipla Ltd.

Asit C Mehta Investment Interrmediates

Cipla's "Future Fit" strategy outlines ambitious growth objectives, including becoming India’s 2nd largest pharmaceutical company, leading South Africa’s prescription and OTC markets, ranking 2nd in U.S. respiratory generics, and doubling international revenue.